• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗抑郁治疗下的改善时间进程:一种生存分析方法。

Time course of improvement under antidepressant treatment: a survival-analytical approach.

作者信息

Stassen H H, Delini-Stula A, Angst J

机构信息

Psychiatric University Hospital Zurich, Research Department, Switzerland.

出版信息

Eur Neuropsychopharmacol. 1993 Jun;3(2):127-35. doi: 10.1016/0924-977x(93)90264-m.

DOI:10.1016/0924-977x(93)90264-m
PMID:8364348
Abstract

A meta-analysis of an earlier multicenter, double-blind efficacy study comparing placebo, oxaprotiline and amitriptyline was performed in order to test the survival-analytical approach in modelling the onset of improvement and response to treatment with antidepressants. The sample consisted of moderately depressed male (n = 154) and female (n = 275) patients (aged 17-73), diagnosed according to DSM-III criteria for major depression. Of these, 120 were treated with oxaprotiline, 120 with amitriptyline and 189 with placebo. Efficacy criteria were Hamilton Depression (HAMD) and Anxiety (HAMA) and Zung Self-Rating scales. Up to eight ratings over a period of 40 days were available for analysis. The results showed that the sensitivity in discriminating between groups was substantially enhanced through the inclusion of drop-outs and consideration of the effect of time to withdrawal from the study due to lack of improvement. Withdrawal from the trial due to inefficacy occurred earliest under placebo (50% within the first 8 days), whereas less than 40% dropped out within the first 12 days under active treatments. The most interesting and unexpected finding of the analysis was that the time course of improvement among responders was independent of the treatment modality, and thus identical in all three groups. Specifically, the efficacy of any of the given treatments was reflected only by the total number of responders or nonresponders. Once triggered, the time course of recovery from illness becomes identical to that of spontaneous remissions as observed, for example, under placebo.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

为了检验生存分析方法在模拟抗抑郁药治疗改善起效和反应方面的效果,对一项早期多中心、双盲疗效研究进行了荟萃分析,该研究比较了安慰剂、奥沙普明和阿米替林。样本包括根据DSM-III重度抑郁症标准诊断的中度抑郁男性(n = 154)和女性(n = 275)患者(年龄17 - 73岁)。其中,120例接受奥沙普明治疗,120例接受阿米替林治疗,189例接受安慰剂治疗。疗效标准为汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)和zung自评量表。在40天的时间里可获得多达八项评分用于分析。结果表明,通过纳入退出者并考虑因改善不足而退出研究的时间影响,区分各组的敏感性显著提高。因无效而退出试验最早出现在安慰剂组(前8天内50%),而在活性治疗组中,前12天内退出者少于40%。该分析最有趣且出乎意料的发现是,反应者改善的时间进程与治疗方式无关,因此在所有三组中相同。具体而言,任何给定治疗的疗效仅由反应者或无反应者的总数反映。一旦触发,疾病恢复的时间进程与例如在安慰剂治疗下观察到的自发缓解的时间进程相同。(摘要截短至250字)

相似文献

1
Time course of improvement under antidepressant treatment: a survival-analytical approach.抗抑郁治疗下的改善时间进程:一种生存分析方法。
Eur Neuropsychopharmacol. 1993 Jun;3(2):127-35. doi: 10.1016/0924-977x(93)90264-m.
2
Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses.抗抑郁药物起效延迟?苏黎世荟萃分析结果调查。
Pharmacopsychiatry. 1996 May;29(3):87-96. doi: 10.1055/s-2007-979551.
3
Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline.
Neuropsychobiology. 1989;22(1):41-8. doi: 10.1159/000118590.
4
Oxaprotiline in the treatment of endogenous depressed inpatients an early clinical trial.奥沙普替林治疗内源性抑郁症住院患者的早期临床试验。
Pharmacopsychiatry. 1985 Jul;18(4):282-5. doi: 10.1055/s-2007-1017382.
5
A clinical test of noradrenergic involvement in the therapeutic mode of action of an experimental antidepressant.去甲肾上腺素能在一种实验性抗抑郁药治疗作用模式中的临床测试。
Biol Psychiatry. 1993 Feb 15;33(4):261-6. doi: 10.1016/0006-3223(93)90292-l.
6
CGP 12.103 A versus clomipramine in the treatment of depressed inpatients--results of a double-blind study.
Pharmacopsychiatry. 1988 Jul;21(4):203-7. doi: 10.1055/s-2007-1014676.
7
A double-blind study of minaprine versus amitriptyline in major depression.米那普明与阿米替林治疗重度抑郁症的双盲研究。
Neuropsychobiology. 1990;24(2):79-83. doi: 10.1159/000119465.
8
[Changes in slow evoked potentials in depressed patients treated with amitriptyline and oxaprotiline].[用阿米替林和奥沙普秦治疗的抑郁症患者慢诱发电位的变化]
Rev Electroencephalogr Neurophysiol Clin. 1987 Sep;17(3):279-87. doi: 10.1016/s0370-4475(87)80065-5.
9
In-patient major depression: is rolipram as effective as amitriptyline?住院重度抑郁症:咯利普兰与阿米替林疗效相同吗?
Eur J Clin Pharmacol. 1991;40(2):127-9. doi: 10.1007/BF00280065.
10
Amitriptyline and oxaprotiline in the treatment of hospitalized depressive patients. Clinical aspects, psychophysiology, and drug plasma levels.
Eur Arch Psychiatry Neurol Sci. 1986;235(6):329-38. doi: 10.1007/BF00381001.

引用本文的文献

1
C-reactive Protein as an Indicator for Antidepressant Response in Late-Onset Depression.C反应蛋白作为晚发性抑郁症抗抑郁反应的指标
Cureus. 2025 Aug 15;17(8):e90133. doi: 10.7759/cureus.90133. eCollection 2025 Aug.
2
Acupuncture as Add-on Therapy to SSRIs Can Improve Outcomes of Treatment for Anxious Depression: Subgroup Analysis of the AcuSDep Trial.针刺作为选择性5-羟色胺再摄取抑制剂(SSRI)的附加疗法可改善焦虑性抑郁症的治疗效果:AcuSDep试验的亚组分析
Neuropsychiatr Dis Treat. 2024 May 16;20:1049-1064. doi: 10.2147/NDT.S446034. eCollection 2024.
3
A Qualitative Study on the Recovery Process and Its Associated Factors in Morita Therapy for Inpatients with Mood Disorders.
一项关于森田疗法治疗心境障碍住院患者康复过程及其相关因素的定性研究。
J Clin Med. 2023 Sep 17;12(18):6016. doi: 10.3390/jcm12186016.
4
A repeated measures cognitive affective bias test in rats: comparison with forced swim test.大鼠重复测量认知情感偏差测试:与强迫游泳测试的比较
Psychopharmacology (Berl). 2023 Nov;240(11):2257-2270. doi: 10.1007/s00213-022-06281-8. Epub 2022 Dec 1.
5
Chronic antidepressant treatment rescues abnormally reduced REM sleep theta power in socially defeated rats.慢性抗抑郁治疗可挽救社交挫败大鼠异常减少的 REM 睡眠θ功率。
Sci Rep. 2021 Aug 18;11(1):16713. doi: 10.1038/s41598-021-96094-0.
6
Drug use evaluation: A two-year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder.药物使用评估:曲唑酮与阿戈美拉汀治疗抑郁症患者的有效性和耐受性的两年回顾性研究。
Brain Behav. 2021 Aug;11(8):e2311. doi: 10.1002/brb3.2311. Epub 2021 Aug 1.
7
Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.延长氯胺酮治疗成人抵抗性抑郁症疗效的策略。
Adv Ther. 2021 Jun;38(6):2795-2820. doi: 10.1007/s12325-021-01732-8. Epub 2021 Apr 30.
8
Ketamine: Leading us into the future for development of antidepressants.氯胺酮:引领抗抑郁药研发的未来。
Behav Brain Res. 2020 Apr 6;383:112532. doi: 10.1016/j.bbr.2020.112532. Epub 2020 Feb 2.
9
Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study.早期症状无改善及加重与重度抑郁症患者对选择性5-羟色胺再摄取抑制剂(SSRI)的治疗反应相关:一项真实世界研究
Neuropsychiatr Dis Treat. 2019 Apr 16;15:957-966. doi: 10.2147/NDT.S196533. eCollection 2019.
10
Is Advancing Circadian Rhythm the Mechanism of Antidepressants?昼夜节律推进是抗抑郁药的作用机制吗?
Psychiatry Investig. 2019 Jul;16(7):479-483. doi: 10.30773/pi.2019.06.20. Epub 2019 Jul 25.